Nav: Home

Study suggests best order of treatment for brain metastases in EGFR lung cancer

January 25, 2017

About 10 percent of lung cancers in the United States and as many as 40 percent in Asia are driven by mutations in the EGFR gene. EGFR targeted treatment advances over the previous decade now result in multiple options for controlling the disease in the body, but due to the reduced ability of many of these drugs to penetrate into the brain, treating of disease in the brain remains challenging. When brain metastases are seen at diagnosis before a patient has tried EGFR-targeted drugs, it has been an open question whether doctors should try drugs alone just in case they work in the brain or move directly to whole-brain radiotherapy or stereotactic radiosurgery (a tightly focused form of radiation) first, followed by targeted medicines. A study published in the Journal of Clinical Oncology looks back at 351 patients with EGFR mutant lung cancer and brain metastases treated at six institutions to offer compelling preliminary evidence as to the best sequence of these techniques: Radiation followed by targeted medicines resulted in the longest overall survival.

"This particular study illustrates a remarkable finding and raises an interesting question. First of all, these patients all had tumors that had spread to the brain. Before we had these EGFR-directed medicines, their average survival would have been less than a year. But for patients treated with the newer medications, even if the cancer has spread to the brain, we are seeing survival ranging from 2-4 years on average, and that is a sign of fantastic progress for at least some lung cancer patients," says Brian Kavanagh, MD, MPH, FASTRO, professor and chair of Radiation Oncology at the University of Colorado Cancer Center, and President of the American Society for Radiation Oncology (ASTRO).

"Because these drugs do not penetrate into the brain very well, we still have to figure out what the best thing to do for tumors that have spread to that location. Do we just use the medicines alone and watch these patients carefully and react accordingly if they have a problem in the brain, or do we take action sooner rather than later and treat the tumors in the brain before they cause a problem? Our observations suggest that the second choice may be a better one for the drugs commonly used as first line EGFR therapy to date," says D. Ross Camidge, MD, PhD, Joyce Zeff Chair in Lung Cancer Research at the CU Cancer Center and director of Thoracic Oncology at the CU School of Medicine.

Specifically, the study evaluated patients in three groups. As above, those that received stereotactic radiosurgery and then an EGFR-directed drug had a median overall survival of 46 months. Those that received whole-brain radiotherapy followed by drug survived a median 30 months. And those that received drug first, followed by either of the radiation protocols as needed, survived a median 25 months.

However, Camidge also adds, "The study wasn't randomized, though, so we can't exclude other factors that might also have influenced the results. For example, radiosurgery may be used in those with a lesser burden of brain disease, whereas whole-brain radiation may be preferred in patients with more disease shortening their survival separately from the impact of the drug or radiation technique."

The study is a collaboration between Kavanagh and Camidge at CU Cancer Center and colleagues at the Yale, Vanderbilt, Memorial Sloan Kettering, Cleveland Clinic, and UCSF Cancer Centers. While this retrospective analysis offers powerful initial evidence for the best use of these therapies, the team hopes that it will also inform a more definitive trial that could test these interventions prospectively.

"Ulitmately, it is possible that there is some middle path that is best. We suspect that some patients with very tiny tumors in the brain, maybe ones that measure only 2-3 millimeters or so, can probably be safely watched closely for a while, and maybe we only need to treat them with radiosurgery when the tumors grow to a somewhat larger size," Kavanagh says. "We are currently in discussions with our colleagues at the collaborating institutions who contributed to this paper to design a study that might answer that question to everyone's satisfaction."
-end-


University of Colorado Anschutz Medical Campus

Related Cancer Articles:

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.